For decades, oncology has faced a brutal wall when treating late-stage cancers: standard therapies often fail once a tumor develops resistance, leaving patients with dwindling options and grim survival timelines.
In a recent conversation on The Financial Survival Network, host Kerry Lutz sat down with Dr. Vlad Vitoc, CEO of MAIA Biotechnology (NYSE Ameri…












